Addex spin-out Neurosterix completes Phase 1 trials of NTX-253 in schizophrenia, targets Phase 2

Bitget2026/10/08 05:01

Addex reported its spin-out Neurosterix completed Phase 1 studies of NTX-253 for schizophrenia. Results have already been generated; no future presentation was specified. Data supported a decision to advance NTX-253 into Phase 2 development. NTX-253 is an M4 receptor positive allosteric modulator aimed at treating schizophrenia. Addex holds a 20% equity stake in Neurosterix, which raised $65 million in Series A financing in April 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080100OMX_____CNEWS_EN_GNW1001276833_en) on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41